Daily Anesthesiology Research Analysis
Top advances span perioperative monitoring, ventilation strategy, and post–cardiac arrest care. A new waveform landmarking tool enables high-fidelity feature extraction from arterial blood pressure and photoplethysmography at scale; a randomized trial suggests PCV-VG may reduce pulmonary stress and shorten stay after complex head-and-neck free flap surgery; and a randomized sub-study indicates targeted mild hypercapnia does not harm—and may improve—right ventricular function after out-of-hospita
Summary
Top advances span perioperative monitoring, ventilation strategy, and post–cardiac arrest care. A new waveform landmarking tool enables high-fidelity feature extraction from arterial blood pressure and photoplethysmography at scale; a randomized trial suggests PCV-VG may reduce pulmonary stress and shorten stay after complex head-and-neck free flap surgery; and a randomized sub-study indicates targeted mild hypercapnia does not harm—and may improve—right ventricular function after out-of-hospital cardiac arrest.
Research Themes
- AI-enabled perioperative waveform analytics
- Intraoperative ventilation strategy and pulmonary outcomes
- Post–cardiac arrest ventilation targets and right ventricular function
Selected Articles
1. Feature extraction tool using temporal landmarks in arterial blood pressure and photoplethysmography waveforms.
An automated ABP/PPG pipeline reliably detected four canonical landmarks with >97% F1 across perioperative and real‑time datasets and derived 852 features per beat. Validation against expert annotations showed error rates <4%, supporting robust generalization. This enables standardized feature engineering for clinical decision support and perioperative machine learning applications.
Impact: Standardized, high-fidelity waveform features are foundational for predictive analytics (e.g., hypotension prediction) and physiology-informed decision support in anesthesia and critical care.
Clinical Implications: Integrating this tool into perioperative monitoring systems could accelerate development of reliable risk stratification and closed‑loop control by providing validated, reproducible features from ABP/PPG.
Key Findings
- Detected four key ABP/PPG landmarks (onset, systolic peak, dicrotic notch, diastolic peak) with average F1 >97% and error <4%.
- Extracted 852 beat-wise features spanning time, statistical, and frequency domains.
- Validated on a large perioperative dataset (MLORD, n=17,327) and a separate real‑time monitor dataset with consistent performance.
Methodological Strengths
- Large-scale validation against expert annotations across two datasets and two waveform modalities (ABP, PPG).
- Comprehensive feature set (852/beat) enabling downstream ML and physiological analyses.
Limitations
- No prospective clinical outcome testing (e.g., impact on alarms, hypotension prediction accuracy) reported.
- Generalizability across vendors, sampling rates, and noisy ward environments remains to be established.
Future Directions: Prospective trials integrating the tool into anesthesia information management systems for hypotension prediction, vasopressor titration, and closed‑loop trials; benchmarking across multi‑center, multi‑vendor data.
This study presents an automatic feature extraction tool that first detects temporal location of landmarks within each cardiac cycle of ABP and PPG waveforms, including the systolic phase onset, systolic phase peak, dicrotic notch, and diastolic phase peak. Then, based on these landmarks, extracts 852 features per cardiac cycle, encompassing time-, statistical-, and frequency-domains. The tool's ability to detect landmarks was evaluated on the perioperative MLORD dataset comprising 17,327 patients and on real-time data collected from a patient monitor (retrospective analysis). When compared with markings by an experienced researcher, the tool demonstrated robust performance across both datasets, waveform types, and all four landmarks, achieving average F1-scores above 97% and error rates below 4%. This tool has significant potential for supporting clinical utilization of ABP and PPG waveform features and for facilitating feature-based machine learning models for various clinical applications where features derived from these waveforms play a critical role.
2. The effects of Pressure-Controlled Volume-Guaranteed ventilation (PCV-VG) on Postoperative Pulmonary Complications (PPCs) of oral and maxillofacial patients undergoing free flap reconstruction: a randomized controlled trial.
In 240 free-flap cases, PCV‑VG lowered peak inspiratory pressure, improved dynamic compliance and oxygenation, and shortened postoperative length of stay (9 vs 10 days). PPCs were numerically lower overall (26.7% vs 34.2%; P=0.051) and significantly lower among tracheotomy patients. Results favor PCV‑VG as a lung-protective intraoperative strategy in this complex surgical cohort.
Impact: Randomized evidence directly informs anesthetic ventilator mode selection for long, high-risk head-and-neck free‑flap procedures.
Clinical Implications: Consider PCV‑VG (pressure‑controlled volume‑guaranteed ventilation) over VCV in high‑risk oral/maxillofacial free‑flap cases to reduce airway pressures, improve compliance and oxygenation, and potentially lower PPCs—especially in tracheotomy patients.
Key Findings
- PCV‑VG reduced peak inspiratory pressure and increased dynamic compliance compared with VCV throughout surgery.
- Oxygenation indices (e.g., OI, PaO2) were better with PCV‑VG; postoperative length of stay was shorter (9 vs 10 days, P=0.041).
- Composite PPCs within 7 days were numerically lower overall (26.7% vs 34.2%, P=0.051) and significantly lower in tracheotomy patients.
Methodological Strengths
- Prospective randomized controlled design with clear intraoperative physiological endpoints.
- Adequate sample size (n=240) for detecting clinically meaningful effects on physiology and hospital stay.
Limitations
- Single-center trial with borderline P value for overall PPCs; blinding of anesthetists to ventilator mode not feasible.
- Composite PPC endpoint; external validity to other surgeries needs confirmation.
Future Directions: Multicenter RCTs powered for PPCs and long-term respiratory recovery; evaluation in other high‑risk surgeries and with standardized lung‑protective bundles.
BACKGROUND: To analyze the effects of pressure-controlled volume-guaranteed ventilation (PCV-VG) and volume-controlled ventilation (VCV) on postoperative pulmonary complications (PPCs) after oral and maxillofacial surgery with free flap reconstruction. METHODS: This was a prospective, randomized, controlled trial comparing two intraoperative ventilation strategies. Two hundred and forty patients who underwent oral and maxillofacial surgery with free flap reconstruction were randomly allocated to either VCV group (n = 120) or the PCV-VG group (n = 120). After induction of anesthesia, for both modes of ventilation, the target tidal volume (VT) was 6 mL/kg and the respiratory rate was adjusted to avoid hypercarbia. The primary outcome was a composite of postoperative pulmonary complications within the first seven postoperative days. The peak and mean inspiratory pressures and dynamic compliance were recorded at T1(the time after the patients entered the operation room), T2 (the time of skin incision), T3 (the time when anastomosing blood vessels), T4 (the time of closure of the incision). And oxygenation index (OI) and arterial partial pressure of oxygen (PaO RESULTS: The two groups had similar characteristics at baseline. 26.7% patients in PCV-VG group, and 34.2% patients in VCV group experienced PPCs within the first 7 days after surgery (P = 0.051). In the first 7 days after surgery, the PCV-VG group had a better postoperative survival probability, but without significant statistical differences (Log-rank test, P = 0.056). But in tracheotomy patients, PCV-VG group had a lower incidence of PPCs (P < 0.05). In addition, the PCV-VG group had a shorter length of stay in hospital after surgery (9 days vs. 10 days, P = 0.041). Furthermore, PCV-VG group had significantly lower peak inspiratory pressure and greater dynamic compliance than VCV group (P < 0.05). At the same time, OI and PaO CONCLUSIONS: For patients undergoing oral and maxillofacial surgery with free flap reconstruction who were at intermediate or high risk of developing PPCs, PCV-VG could shorten the length of stay in hospital and showed a trend toward being superior to VCV in its ability to provide ventilation with lower peak inspiratory pressure, greater dynamic compliance, and better oxygenation. Meanwhile, in tracheotomy patients, the PCV-VG group had a lower incidence of PPCs. TRIAL REGISTRATION: Chinese Clinical Trial Registry, www.chictr.org.cn , number: ChiCTR2200060865; Registered on June 12, 2022.
3. The effects of targeted mild hypercapnia on right ventricular function after out-of-hospital cardiac arrest. A sub-study of the TAME cardiac arrest trial.
In a pre-planned single-center sub-study of the randomized TAME trial (n=111), targeted mild hypercapnia after OHCA improved RV systolic indices (higher TAPSE, S', FAC) and reduced RV dysfunction (25% vs 64%) and failure (8 vs 22). RV failure was associated with higher 6‑month mortality (HR 2.89).
Impact: Ventilation targets after cardiac arrest remain debated; these randomized data suggest mild hypercapnia is not detrimental to the RV and may be protective, informing post‑resuscitation ventilation strategies.
Clinical Implications: Post‑OHCA ventilation targeting mild hypercapnia (elevated PaCO2) may be considered safe for RV function and potentially beneficial; careful hemodynamic and echocardiographic monitoring remains essential.
Key Findings
- During the intervention, RV systolic function indices (TAPSE, S', FAC) were higher in the mild hypercapnia group.
- RV systolic dysfunction and RV failure were significantly less frequent with mild hypercapnia (25% vs 64%; 8 vs 22 patients).
- RV failure independently associated with increased 6‑month mortality (HR 2.89, 95% CI 1.37–6.10).
Methodological Strengths
- Randomized allocation from parent RCT with pre-planned sub-study design.
- Objective assessment with echocardiography and right heart catheterization in a subset.
Limitations
- Single-center sub-study with modest sample size; echocardiographic measures are surrogate endpoints.
- Generalizability and impact on hard clinical outcomes require multicenter confirmation.
Future Directions: Multicenter RCTs to test clinical outcomes (neurologic recovery, survival) with mild hypercapnia strategies and to define optimal PaCO2 targets individualized by RV function.
BACKGROUND: Targeting hypercapnia during invasive mechanical ventilation with subsequent respiratory acidosis may impair right ventricular (RV) function and cause RV failure. RV dysfunction is common after cardiac arrest and may be associated with poor outcomes. RESEARCH QUESTION: Does targeting mild hypercapnia after out-of-hospital cardiac arrest (OHCA) adversely affect RV function, and is RV failure after OHCA associated with increased mortality? STUDY DESIGN AND METHODS: Single-center, pre-planned sub-study of the Targeted Therapeutic Mild Hypercapnia After Resuscitated Cardiac Arrest (TAME) trial. Patients were randomized to mild hypercapnia (PaCO RESULTS: A total of 111 patients were randomized and evaluated with echocardiography. RHC was performed in 84 patients. TAPSE was similarly reduced in both treatment groups at ICU admission. During the intervention, TAPSE, S' and FAC were higher in the hypercapnia-group (p <0.05). Accordingly, 13 (25%) patients in the hypercapnia-group had RV systolic dysfunction compared with 37 (64%) in the normocapnia-group (p <0.001). RV failure was present in 30 patients: 8 in the hypercapnia-group and 22 in the normocapnia-group (p =0.011). RV failure was associated with increased six-month mortality: Hazard ratio of 2.89 (95 % CI 1.37-6.10), p=0.005. INTERPRETATION: Among patients resuscitated from OHCA, targeting mild hypercapnia compared with normocapnia was not associated with worsened RV function, but rather with less RV dysfunction and failure. RV failure was associated with increased six-month mortality. CLINICAL TRIAL REGISTRATION: NCT03114033.